SCHEMBL2709778

SCHEMBL2709778

COc1cc(F)c(-c2c3ccccc3c(-c3c(F)c(F)c(F)c(F)c3F)c3cccc(F)c23)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.34
MIF P14174 1/20 0.33
KDM1A O60341 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
NPC1 O15118 2/20 0.32
TAAR1 Q96RJ0 1/20 0.32
TSHR P16473 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
RELA Q04206 1/20 0.31
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
CDK2 P24941 1/20 0.31
FLT3 P36888 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2710330 0.94 NFE2L2 (0.38) NFE2L2RAB9ASMN1; SMN2ALDH1A1MIF
SCHEMBL2710065 0.93 NFE2L2 (0.33) NFE2L2RAB9ASMN1; SMN2ALDH1A1MIF
SCHEMBL2725925 0.93 NFE2L2 (0.34) NFE2L2RAB9ASMN1; SMN2ALDH1A1MIF
SCHEMBL2725617 0.93 ALDH1A1 (0.33) NFE2L2RAB9ASMN1; SMN2ALDH1A1MIF
SCHEMBL2940995 0.91 ALDH1A1 (0.34) NFE2L2RAB9ASMN1; SMN2ALDH1A1MIF
SCHEMBL2726247 0.91 ALDH1A1 (0.34) NFE2L2RAB9ASMN1; SMN2ALDH1A1MIF
SCHEMBL12086114 0.90 GRM8 (0.33) NFE2L2ALDH1A1MIFCYP1A2
SCHEMBL2728432 0.90 GRM8 (0.33) NFE2L2ALDH1A1MIFCYP1A2
SCHEMBL2724680 0.90 MAOA (0.35) RAB9ASMN1; SMN2ALDH1A1KDM1AMAOA
SCHEMBL2727079 0.89 TAAR1 (0.38) NFE2L2RAB9ASMN1; SMN2ALDH1A1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
EP-2445987-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS Cyalume Technologies, Inc (US) 2012-05-02 EP disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
WO-2010151654-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECHNOLOGIES, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 NFE2L2 346/4885RAB9A 2786/4885SMN1; SMN2 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.